HPK1-IN-32

Cat. No.:	HY-148847
CAS No.:	2766481-17-6
Molecular Formula:	$C_{28}H_{37}FN_8O_2$
Molecular Weight:	536.64
Target:	MAP4K
Pathway:	MAPK/ERK Pathway
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (93.17 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8634 mL	9.3172 mL	18.6345 mL
	5 mM	0.3727 mL	1.8634 mL	3.7269 mL
	10 mM	0.1863 mL	0.9317 mL	1.8634 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.66 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.66 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC_{50} of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases[1].

IC_{50} & Target

HPK1

In Vitro

HPK1-IN-32 (Example A34, 0-2 μM, 2 h) inhibits cellular pSLP76 activity with an IC_{50} of 65 nM in Jurkat cell line[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sanjia XU, et al. 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof. Patent. WO2022068848.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA